Patients with JMML have genetic abnormalities in granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathways, such as inactivation of NF1 or mutations in PTPN11, NRAS, KRAS, and CBL [1, 2]. The gene discussed is CSF2; the disease is juvenile myelomonocytic leukemia.